Vir Biotechnology, Inc. Stock News

VIR vs. ILMN: Which Stock Is the Better Value Option?

Vir Biotechnology, Inc. (VIR) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analyst

VIR vs. ILMN: Which Stock Is the Better Value Option?

Vir Biotechnology, Inc. (VIR) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analyst

Vir Biotechnology <> the maker of COVID-19 antibody therapy sotrovimab is trading lower for the second consecutive session on Monday

VIR beat earnings estimates in the fourth quarter on higher sotrovimab revenues for COVID-19 patients.

VIR beat earnings estimates in the fourth quarter on higher sotrovimab revenues for COVID-19 patients.

Vir Biotechnology, Inc. (VIR) delivered earnings and revenue surprises of 50.77% and 21.33%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the sto

Vir Biotechnology press release (VIR): Q4 GAAP EPS of $3.92 beats by $1.29.Revenue of $812.7M (+46876.9% Y/Y) beats by $189.8M.Cash, Cash Equivalents and Investments: As of December…

– Significant progress made increasing global patient access to sotrovimab; approximately 1.7 million doses sold to date – – $917.2 million of sotrovimab collaboration revenue recognized in 2021 – – Multiple commercial and clinical value drivers expected across the portfolio in 2022 – SAN

Vir Biotechnology, Inc. (VIR) delivered earnings and revenue surprises of 50.77% and 21.33%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the sto

In last trading session, Vir Biotechnology Inc. (NASDAQ:VIR) saw 1.18 million shares changing hands with its beta currently measuring 0. Company’s recent per share price level of $27.80 trading at -$1.68 or -5.70% at ring of the bell on the day assigns it a market valuation of $3.74B. That closing price of VIR’s stock is … Vir Biotechnology Inc. (NASDAQ:VIR) Is Now -3.78% Below Its 52-Week Low. How Long Will It Continue To Rise? Read More »

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Adagio Appoints COO David Hering As Interim CEO Adagio Therapeutics, Inc., (NASDAQ: ADGI) announced th

The U.S. Food and Drug Administration noted that GlaxoSmithKline (GSK) and Vir Biotechnology''s (VIR) coronavirus antibody therapy should not be used in areas with circulation of…

Vir Biotechnology (NASDAQ:VIR) is scheduled to announce Q4 earnings results on Thursday, February 24th, after market close.The consensus EPS Estimate is $1.56 (+288.0% Y/Y) and…